2025 ASCO Highlights Enduring-ASCO Highlights Recording

Video Transcription

Video Summary

In a recent ISLC webinar titled "ASCO 2025 Highlights," experts from various cancer research institutions discussed significant developments in lung cancer treatment, focusing on neoadjuvant therapies. The event was moderated by Dr. Luis Reyes and Dr. Kaushal Parikh, who introduced several key studies. Dr. Jamie Schaft highlighted the Phase 3 NeoAdora study, emphasizing the efficacy of neoadjuvant osomeritinib with or without chemotherapy for patients with EGFR mutant non-small cell lung cancer, indicating improved surgery prospects and adjuvant therapy outcomes compared to traditional chemotherapy alone.<br /><br />Dr. Patrick Forde presented the Checkmate 816 trial findings, where neoadjuvant nivolumab plus chemotherapy showed a notable survival advantage over chemotherapy alone in resectable non-small cell lung cancer patients. By examining baseline characteristics, this trial suggested that PCR significantly correlated with improved survival, offering a new potential paradigm for treatment strategies.<br /><br />Dr. Julia Rotov discussed an adaptive strategy using ctDNA dynamics to guide treatment intensification for non-small cell lung cancer, which demonstrated promising progression-free survival and reduced chemotherapy exposure.<br /><br />Lastly, Dr. Yanis Monzias presented the DELFI-304 trial results, where Tarlatamab showed superior survival outcomes as a second-line treatment for small cell lung cancer, positing it as a potential new standard of care. The session highlighted ongoing advancements and the potential for these innovative therapies to improve patient outcomes significantly.

Keywords

ASCO 2025

lung cancer

neoadjuvant therapy

NeoAdora study

osomeritinib

Checkmate 816 trial

nivolumab

ctDNA dynamics

Tarlatamab